20:48 , Oct 23, 2018 |  BC Extra  |  Company News

Management tracks: Celgene, Seres, AC Immune

Celgene Corp. (NASDAQ:CELG) hired Alise Reicin as president of global clinical development, a newly created position. She was SVP and head of global clinical development in R&D at the EMD Serono business of Merck KGaA...
21:56 , Jul 26, 2018 |  BC Extra  |  Company News

Biogen, Eisai AD readout leads to stock dive

Biogen Inc. (NASDAQ:BIIB) sank $39.09 (10%) to $344.74 on Thursday after reporting detailed data from a Phase II trial of Alzheimer's disease candidate BAN2401. Although the data showed that the anti-β amyloid therapy slowed cognitive...
23:25 , Jul 6, 2018 |  BC Extra  |  Financial News

Biotech stocks rise after positive AD data

Biotech indexes gained Friday after Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) reported 18-month data for BAN2401 to treat Alzheimer's disease. Biogen gained $58.67 (20%) to $357.48, adding about $12.3 billion in market cap,...
16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
21:45 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Genentech begins Phase II of AC Immune's anti-Tau mAb for AD

AC Immune S.A. (NASDAQ:ACIU) said the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) started a Phase II trial of Anti Tau mAb (RO7105705) to treat prodromal-to-mild Alzheimer's disease. The trial start triggered a CHF14 million...
03:13 , Jun 9, 2017 |  BC Week In Review  |  Company News

AC Immune, Essex partner to develop undisclosed neurology candidate

AC Immune S.A. (NASDAQ:ACIU) partnered with Essex Bio-Technology Ltd. (HKSE:1061) to develop an undisclosed biologic. The companies said the candidate acts "on a unique neuroprotective mechanism" and will be developed to treat Alzheimer's disease (AD)...
21:08 , May 25, 2017 |  BC Extra  |  Company News

Merck obtains rights to Teijin's tau candidate

Teijin Pharma Ltd. (Tokyo, Japan) granted Merck & Co. Inc. (NYSE:MRK) exclusive rights to an undisclosed preclinical antibody targeting microtubule-associated protein tau (tau; MAPT; FTDP-17). Merck plans to develop the candidate to treat Alzheimer’s disease....
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
16:03 , Feb 8, 2017 |  BioCentury  |  Finance

Hurdle jumping

With the biotech indices brushing off 2016’s latest major milestone, biotech now appears to be free of any events that could jolt the sector in the year’s waning weeks. Investors had circled two major November...
03:37 , Dec 17, 2016 |  BioCentury  |  Product Development

Not dead yet

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc. ’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for...